Lung cancer: ICAM, a new predictor for treatment response and survival
Researchers at the Ireland Cancer Center of University Hospitals of Cleveland have found a promising, novel biomarker that may be used to predict the survival of patients with advanced lung cancer and their response to treatment. Afshin Dowlati at the Ireland Cancer Center found that patients with a low level of the biomarker ICAM had a better chance of survival and an increased response to chemotherapy.
This entry was posted on Wednesday, August 23rd, 2006 at 9:29 am and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.